This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



# Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

# Studies on Nucleoside Analogs. XXV.¹) Synthesis of 5, 7-Dioxopyrimido[5,4-e]-AS-Triazine Glycosides

Haruo Ogura<sup>a</sup>; Hiroshi Takahashi<sup>a</sup>; Kikuko Ohokubo<sup>a</sup>

<sup>a</sup> School of Pharmaceutical Sciences, Kitasato University 5-9-1 Shirokane, Minato-ku, Tokyo, Japan

**To cite this Article** Ogura, Haruo , Takahashi, Hiroshi and Ohokubo, Kikuko(1982) 'Studies on Nucleoside Analogs. XXV.') Synthesis of 5, 7-Dioxopyrimido[5,4-e]-AS-Triazine Glycosides', Nucleosides, Nucleotides and Nucleic Acids, 1: 2, 147—154

To link to this Article: DOI: 10.1080/07328318208078829 URL: http://dx.doi.org/10.1080/07328318208078829

## PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

STUDIES ON NUCLEOSIDE ANALOGS. XXV.  $^{1)}$  SYNTHESIS OF 5,7-DIOXOPYRIMIDO[5,4-e]-AS-TRIAZINE GLYCOSIDES

Haruo Ogura\*, Hiroshi Takahashi, and Kikuko Ohokubo

School of Pharmaceutical Sciences, Kitasato University
5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan

#### Abstract

The reaction of glycosyl isothiocyanates (la, b, c, d, e) with 5,6-diamino-1,3-dimethyluracil gave the respective 1-glycosyl-3-(6-amino-1,3-dimethyl-2,4-dioxopyrimidine-5-yl)thioureas (2a, b, c, d, e) in excellent yields. Treatment of these thioureas with NBS afforded the respective 5,7-dioxopyrimido-[5,4-e]-as-triazine glycosides (4a, b, c, d, e) in good yields.

Fervenulin, which has some biological activities, was isolated in  $1960^2$  and its structure was confirmed by Robins <u>et al.</u><sup>3)</sup> as 6.8-dimethyl-5.7-dioxo-5.6.7.8-tetrahydro-pyrimido[5.4-<u>e</u>]-as-triazine, which is isomeric with toxoflavin.

Previously, we have reported a synthetic method for sulfur containing nucleoside analogs utilizing glycosyl isothiocyanates as starting materials, <u>e. g.</u>, 1,2,4-triazole glycosides,  $^{5)}$  1,2,4,6-thiatriazine-§-glycosides,  $^{6)}$  glycosylaminoisothiazolo[3,4-<u>d</u>]pyrimidines,  $^{7)}$  and 1,3,5-triazine glycosides.  $^{8)}$ 


We have also reported a synthetic method for glycosylamino-pyrimido  $[4,5-\underline{e}]-1,3,4$ -thiadiazines,  $^{9)}$  polyhydroxyalkyl theophyllines,  $^{10)}$  and 1,2,4-triazole glycosides  $^{11)}$  by the NBS ( $\underline{N}$ -bromosuccinimide) oxidation of glycosyl thiocarboxamides and Schiff bases.

In this paper, we wish to report a convenient method for synthesizing nucleoside analogs possessing the pyrimido  $[5,4-\underline{e}]$ -as-triazine ring system.

Treatment of 2,3,4,6-tetra- $\underline{0}$ -acetyl- $\beta$ - $\underline{D}$ -glucoypranosyl- (la), 2,3,4-tri- $\underline{0}$ -acetyl- $\alpha$ - $\underline{D}$ -arabinopyranosyl- (lb) or 2,3,5-tri- $\underline{0}$ -benzoyl- $\beta$ - $\underline{D}$ -ribofuranosyl isothiocyanate (lc) with 5,6-diamino-1,3-dimethyluracil gave the respective 1-(2,3,4,6-tetra- $\underline{0}$ -acetyl- $\beta$ - $\underline{D}$ -glucopyranosyl)- (2a), 1-(2,3,4-tri- $\underline{0}$ -acetyl- $\alpha$ - $\underline{D}$ -arabino-pyranosyl)- (2b), or 1-(2,3,5-tri- $\underline{0}$ -benzoyl- $\beta$ - $\underline{D}$ -ribofuranosyl)-3-(6-amino-1,3-dimethyl-2,4-dioxopyrimidin-5-yl)thiourea (2c) in 94-97% yields. Treatment of 2a-2c with methyl iodide gave the respective glycosylaminotheophyllines (3a, b, c) through a cyclodesulfurization reaction. (12) Similar treatment of hepta- $\underline{0}$ -acetyl- $\beta$ - $\underline{D}$ -lactosyl- (ld) or hepta- $\underline{0}$ -acetyl- $\beta$ - $\underline{D}$ -maltosyl isothiocyanate (1e) with 5,6-diamino-1,3-dimethyluracil in dry acetonitrile under reflux afforded the respective thioureas (2d and e) in 87-95% yields.

The nuclear magnetic resonance (NMR) spectra of 2d and e showed a broad singlet at  $\delta$  6.55-6.56 due to the amino group at the 6-position of the pyrimidine ring. Signals of N-CH<sub>3</sub> group appeared at  $\delta$  3.06-3.08 and  $\delta$  3.28 as singlets, respectively. A doublet peak at  $\delta$  7.68 and  $\delta$  7.76 (<u>J</u>=8.0 Hz) due to the NH group was attributed to the anomeric position. Another NH proton was observed at  $\delta$  8.36-8.40 as a broad singlet, and both NH signals disappeared on addition of D<sub>2</sub>O.

The oxidative cyclization reaction of these thioureas was observed with NBS. When 1-glucopyranosyl-3-(6-amino-1,3-dimethyl-



2,4-dioxopyrimidin-5-yl)thiourea (2a) was treated with NBS at 0-5°C for 30 min, the cyclized product (4a) was obtained in 92% yield after chromatography. In this cyclization reaction, route a is probable. Similarly, ring closure of these thioureas (2b, c; 2d, e) was successful with NBS in chloroform to obtain the respective pyrimido[5,4-e]-as-triazine glycosides (4b, c, d, e) in good yields. The thione structure of the product was established by comparison of the UV spectrum of 4b with the previous values from a report. 13)

In the mass spectrum of thiourea (2b), the molecular ion was observed at  $\underline{m}/\underline{z}$  487 (4.2%) and the cleavage of the glycosidic bond produced  $\underline{m}/\underline{z}$  259 (100%) (sugar moiety). However, in glycoside 4b, the molecular ion was observed at  $\underline{m}/\underline{z}$  485 (2.3%) and the loss of the sulfur atom produced  $\underline{m}/\underline{z}$  353 (86%).

In conclusion, the syntheses of the titled glycosides were conveniently accomplished by using NBS as an oxidative cyclization reagent.

### EXPERIMENTAL

All melting points are uncorrected. Infrared (IR) spectra were measured with a JASCO A-2 spectrometer and NMR spectra with a Varian T-60 spectrometer. Tetramethyl silane was used as an internal standard. Mass spectra (MS) were determined with a JMS-D-100 spectrometer using a direct inlet system at 75 eV. Optical rotations were measured in CHCl<sub>3</sub> or MeOH solution in a 50 mm cell with a JASCO DIP-181 automatic polarimeter. Thinlayer chromatography was performed on pre-coated plates (layer thickness 0.2 mm) of Silica gel F 254 (E. Merck, Darmstadt, Germany).

1-Glycosyl-3-(6-amino-1,3-dimethyl-2,4-dioxopyrimidin-5-yl)thioureas (2a, b, c) ---- These thioureas (2a, b, c) were prepared by our reported method. 12) 1-[0-(2,3,4,6-Tetra-0-acetyl-β-D-galactopyranosyl)-(1,4)-(2,3,6-tri-0-acetyl-β-D-glucopyranosyl)]-3-(6-amino-1,3-dimethyl-2,4-dioxopyrimidin-5-yl)thiourea (2d) ----- A mixture of hepta-0-acetyl-β-D-lactosyl isothiocyanate  $^{14}$ ) (1d, 680 mg, 0.001 mol) and 5,6-diamino-1,3-dimethyluracil (170 mg, 0.001 mol) in dry MeCN (10 ml) was refluxed for 6 hr on a water bath, then evaporated to dryness under reduced pressure. The residue was chromatographed on silica gel with CHCl<sub>3</sub>-acetone (97:3) to give 2d as a syrup in 92% yield. Crystallization from EtOH-Et<sub>2</sub>O (1:2) gave 2d as an yellow powder (737 mg, 87%), mp 164-169°C, [α]D<sup>27</sup> +22.0° (c=1.0, CHCl<sub>3</sub>), Rf 0.44 in 9:1 CHCl<sub>3</sub>-MeOH, NMR (δ, DMSO-d<sub>6</sub>): 3.06 (s, 3H, NMe), 3.28 (s, 3H, NMe), 6.55 (bs, 2H, NH<sub>2</sub>), 7.68 (bs, 1H, NH), and 8.36 (bs, 1H, NH). MS: m/z 846 (M<sup>+</sup>). Anal. Calcd for C<sub>33</sub>H<sub>45</sub> O<sub>19</sub>N<sub>5</sub>S: C, 46.74; H, 5.35; N, 8.26. Found: C, 46.80; H, 5.38; N, 8.25.

 $1-[0-(2,3,4,6-\text{Tetra}-0-\text{acety}1-\beta-D-\text{glucopyranosy}1)-(1,4)-(2,3,4$  $tri_0$ -acetyl- $\beta$ -D-glucopyranosyl)]-3-(6-amino-1,3-dimethyl-2,4dioxopyrimidin-5-yl)thiourea (2e) ---- A mixture of hepta-0acetyl- $\beta$ -D-maltosyl isothiocyanate<sup>14</sup> (1e, 677 mg, 0.001 mol) and 5,6-diamino-1,3-dimethyluracil (170 mg, 0.001 mol) in dry MeCN (15 ml) was refluxed for 8 hr and treated by a similar manner described above for 2d. Crystallization from EtOH-Et2O (1:2) afforded 2e as fine colorless needles (805 mg, 95%), mp 157-162°C,  $[\alpha]_D^{27} +59.0$ ° (c=1.0, CHCl<sub>3</sub>), Rf 0.57 in 9:1 CHCl<sub>3</sub>-MeOH, NMR ( $\delta$ , DMSO-d $_6$ ): 3.08 (s, 3H, NMe), 3.28 (s, 3H, NMe), 6.56 (bs, 2H, NH<sub>2</sub>), 7.76 (bs, 1H, NH), and 8.40 (bs, 1H, NH). MS:  $\underline{m}/\underline{z}$  847 (M<sup>+</sup>). Anal. Calcd for C<sub>33</sub>H<sub>45</sub>O<sub>19</sub>N<sub>5</sub>S: C, 46.74; H, 5.35; N, 8.26. Found: C, 46.72; H, 5.38; N, 8.30. 2-Glycosyl-6, 8-dimethyl-5, 7-dioxopyrimido[5, <math>4-e]-as-triazine-3-thiones (4a, b, and c) (Table I) ---- NBS (177 mg, 0.001 mol) was added to an ice-cooled solution of 2a, b, or c (0.001 mol) in CHCl3 (10-15 ml) under stirring. After stirring at 0-5°C for

TABLE 1.	(4a, b, c	Z-GIYCOSYL-b,8-dimetn (4a, b, c, d, and e)	y1-5,/-d10xol	pyrımıdo	TABLE 1. 2-GIYCOSYI-b,8-dimetnyI-5,/-dioxopyrimido[5,4- <u>e</u> ]- <u>as</u> -triazine-3-thion (4a, b, c, d, and e)	ne-3-thìon
Соmpound	Yield (	Compound Yield (%) mp (°c)	NMR (6, CDC13) NMe NH	C13) NH	$[\alpha]_{D}^{27}$ (c 1.0, MeOH)	$(\overline{z}/\overline{u})$ SW
<b>4</b> a	92	182-185	3.43, 3.52	6.35	-25.0	557 (M <sup>+</sup> )
Д	98	157-159	3.45, 3.54	6.30	-37.2	485 (M <sup>+</sup> )
υ	06	syrup <mark>a</mark>	3.12, 3.47	7.42	+4.0	
Ō	95	150-153	3.24, 3.40	6.60,	$6.60, 8.40^{\frac{1}{2}} - 50.3^{\frac{2}{3}}$	
a	88	134-137	3.25, 3.35	7.45 <u>b</u>		

a: Rf 0.63 t. 1. c. [silica gel, benzene-acetone (3:2)]

b: in DMSO-d<sub>6</sub>

c: in CHCl<sub>3</sub>

0.5-1.5 hr, the reaction solution was washed with sat. NaHCO<sub>3</sub> solution and H<sub>2</sub>O. The organic layer was dried over MgSO<sub>4</sub>, and evaporated to leave a slight brownish residue. The residue was chromatographed on silica gel with CHCl<sub>3</sub>-acetone (9:1) to give 4a, b, or c, respectively. 4a: Anal. Calcd for  $C_{21}H_{27}O_{11}N_5S$ : C, 45.22; H, 4.88; N, 12.57. Found: C, 45.27; H, 4.94; N, 12.51. 4b: Anal. Calcd for  $C_{18}H_{23}O_{9}N_5S$ : C, 44.53; H, 4.78; N, 14.43. Found: C, 44.58; H, 4.82; N, 14.43. 4c: Anal. Calcd for  $C_{33}H_{29}O_{9}N_5S$ : C, 59.01; H, 4.35; N, 10.43. Found: C, 59.05; H, 4.38; N, 10.40.

 $2-[\underline{0}-(2,3,4,6-\text{Tetra}-\underline{0}-\text{acetyl}-\beta-\underline{D}-\text{galactopyranosyl})-(1,4)-\underline{0}-2,3,6-$ 

 $tri_0-acetyl_3-b-glucopyranosyl)$ ]-6,8-dimethyl-5,7-dioxopyrimido-[5,4-e]-as-triazine-3-thione (4d) and 2-[0-(2,3,4,6-Tetra-0-acet $y1-\alpha-D-g1ucopyranosy1)-(1+4)-O-(2,3,6-tri-O-acety1-\beta-D-g1uco-acety1-3-a$ pyranosyl)]-6,8-dimethyl-5,7-dioxopyrimido[5,4- $\underline{e}$ ]- $\underline{as}$ -triazine-3-one (4e) ---- To a solution of 2d or e (0.001 mol) in CHCl<sub>3</sub> (20-25 ml), NBS (180 mg, 0.001 mol) was added with stirring. After 1-1.5 hr, the reaction solution was treated as described above for 4a. The residue was chromatographed on silica gel, and elution with CHCl3-acetone (97:3) gave the cyclized product as a syrup. Crystallization from EtOH-Et20 (1:1) or EtOH-iso-Pr20 (1:1) afforded 4d (800 mg, 95%) as yellow needles, or 4e (740 mg, 95%)88%) as colorless fine needles, respectively. 4d: Rf 0.52 in 9:1 CHCl<sub>3</sub>-MeOH, IR  $\nu_{\text{max}}^{\text{KBr}}$  cm<sup>-1</sup>: 3250 (NH) and 1740 (OCOCH<sub>3</sub>). Anal. Calcd for C<sub>33</sub>H<sub>43</sub>O<sub>19</sub>N<sub>5</sub>S: C, 46.86; H, 5.12; N, 8.28. Found: C, 46.91; H, 5.10; N, 8.32. 4e: Rf 0.62 in 9:1 CHCl<sub>3</sub>-MeOH, IR  $\nu_{\text{max}}^{\text{KBr}}$  cm<sup>-1</sup>: 3250 (NH) and 1740 (OCOCH<sub>3</sub>). MS: m/z 813 (M<sup>+</sup>-32). Anal. Calcd for C33H43O19N5S: C, 46.86; H, 5.12; N, 8.28. Found: C, 46.80; н, 5.16; N, 8.30.

Acknowledgement This work was supported in part by a Grant-in-Aid for Scientific Research (57370032) from the Ministry of Education, Science and Culture, Japan.

#### REFERENCES

- 1) Previous paper (Part XXIV): H. Ogura and H. Takahashi, <u>Heterocycles</u>, <u>17</u>, 87 (1982). This also constitutes Part XLIV in a series entitled "Studies on Heterocyclic Compound".
- 2) T. E. Eble, E. C. Olson, C. M. Lange, and J. W. Shell,
  "Fervenulin: Isolation and Characterization" in Antibiotics
  Annual 1959-1960, Antibiotica Inc., New York 1960, p. 127.
- 3) G. D. Davis, Jr., R. K. Robins, and C. C. Cheng, <u>J. Org. Chem.</u>, 26, 5256 (1979); idem., <u>J. Am. Chem. Soc.</u>, 84, 1724 (1962).
- 4) H. Takahashi, N. Nimura, and H. Ogura, <u>Chem. Pharm. Bull.</u>,
   27, 1130 (1979); <u>idem.</u>, <u>ibid.</u>, 27, 1143 (1979): H. Takahashi,
   K. Takeda, N. Nimura, and H. Ogura, <u>ibid.</u>, 27, 1137 (1979).
- 5) H. Ogura, H. Takahashi, and O. Sato, <u>ibid.</u>, <u>29</u>, 2188 (1981).
- 6) H. Ogura, H. Takahashi, and O. Sato, ibid., 29, 1843 (1981).
- 7) H. Takahashi, N. Nimura, and H. Ogura, <u>ibid</u>.,  $\underline{\underline{27}}$ , 1147 (1979).
- 8) H. Ogura, H. Takahashi, and O. Sato, <u>ibid</u>., <u>29</u>, 1838 (1981).
- 9) H. Ogura, H. Takahashi, and E. Kudo, <u>J. Carbohydr. Nucleosides</u>
  <u>Nucleotides</u>, 5, 329 (1978).
- 10) H. Ogura, H. Takahashi, and M. Sakaguchi, <u>Heterocycles</u>, <u>3</u>, 93 (1975).
- 11) H. Ogura, H. Takahashi, and O. Sato, <u>Chem. Pharm. Bull.</u>, <u>29</u>, 1838 (1981).
- 12) H. Takahashi, N. Nimura, N. Obata, H. Sakai, and H. Ogura, <u>ibid.</u>, <u>27</u>, 1153 (1979).
- 13) The UV spectrum of compound 4b shows an absorption at 350 nm, indicating the presence of the thione form. UV  $\lambda_{\max}^{\text{MeOH}}$  nm (log  $\epsilon$ ): 220 (4.2), 290 (3.8), 350 (2.8). For the thionethiol equilibrium, see: A. Morton and A. L. Stubb, <u>J. Chem. Soc.</u>,  $\frac{1936}{2}$ , 1321: E. Spinner, <u>ibid.</u>,  $\frac{1960}{2}$ , 1237: H. Ogura, H. Takahashi, and K. Takeda, <u>Chem. Pharm. Bull.</u>,  $\frac{29}{2}$ , 1832 (1 (1981).
- 14) H. Ogura and H. Takahashi, <u>NIPPON KAGAKU KAISHI</u>, accepted. RECEIVED: April 7, 1982